BioMarin Pharmaceutical research and development expenses for the twelve months ending September 30, 2024 were $0.780B, a 9.34% increase year-over-year.
BioMarin Pharmaceutical annual research and development expenses for 2023 were $0.747B, a 14.96% increase from 2022.
BioMarin Pharmaceutical annual research and development expenses for 2022 were $0.65B, a 3.31% increase from 2021.
BioMarin Pharmaceutical annual research and development expenses for 2021 were $0.629B, a 0.11% increase from 2020.
BioMarin Pharmaceutical Research and Development Expenses 2010-2024 | BMRN